CCCC
NASDAQ · Biotechnology
C4 Therapeutics Inc
$3.15
+0.05 (+1.61%)
Open$3.13
Previous Close$3.10
Day High$3.23
Day Low$3.04
52W High$5.17
52W Low$1.69
Volume—
Avg Volume3.13M
Market Cap382.61M
P/E Ratio—
EPS$-1.00
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,145.7% upside
Current
$3.15
$3.15
Target
$39.24
$39.24
$29.92
$39.24 avg
$50.68
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 51.68M | 49.24M | 17.10M |
| Net Income | -150,969,309 | -129,463,914 | 3.03M |
| Profit Margin | -292.1% | -277.5% | 17.7% |
| EBITDA | -162,864,727 | -147,424,002 | 5.37M |
| Free Cash Flow | — | — | 3.54M |
| Rev Growth | +5.0% | +5.0% | +6.2% |
| Debt/Equity | — | — | 1.00 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |